Silexion Therapeutics (SLXN) Projected to Post Quarterly Earnings on Tuesday

Silexion Therapeutics (NASDAQ:SLXN) is expected to be releasing its results before the market opens on Tuesday, May 12th. Analysts expect Silexion Therapeutics to post earnings of ($1.29) per share for the quarter.

Silexion Therapeutics Stock Performance

Shares of NASDAQ:SLXN traded down $0.02 during midday trading on Tuesday, hitting $0.62. The company’s stock had a trading volume of 52,932 shares, compared to its average volume of 57,236. Silexion Therapeutics has a fifty-two week low of $0.47 and a fifty-two week high of $22.36. The stock has a market capitalization of $2.05 million, a price-to-earnings ratio of -0.06 and a beta of -0.29. The stock’s 50 day simple moving average is $1.30 and its 200 day simple moving average is $2.07. The company has a debt-to-equity ratio of 0.60, a quick ratio of 2.41 and a current ratio of 2.41.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Wednesday, March 18th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Silexion Therapeutics currently has an average rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.